Have questions? Visit https://www.reddit.com/r/SNPedia

rs11045585

From SNPedia

Orientationplus
Stabilizedplus
Geno Mag Summary
(A;A) 2 24% chance (lower than average) of docetaxel-induced leukopenia/neutropenia
(A;G) 2 63% chance (higher than average) of docetaxel-induced leukopenia/neutropenia
(G;G) (no data; implied high chance of docetaxel-induced leukopenia/neutropenia)
ReferenceGRCh38 38.1/141
Chromosome12
Position20892760
GeneSLCO1B3
is asnp
is mentioned by
dbSNPrs11045585
ebirs11045585
HLIrs11045585
Exacrs11045585
Varsomers11045585
Maprs11045585
PheGenIrs11045585
hapmaprs11045585
1000 genomesrs11045585
hgdprs11045585
ensemblrs11045585
gopubmedrs11045585
geneviewrs11045585
scholarrs11045585
googlers11045585
pharmgkbrs11045585
gwascentralrs11045585
openSNPrs11045585
23andMers11045585
23andMe allrs11045585
SNP Nexus

SNPshotrs11045585
SNPdbers11045585
MSV3drs11045585
GWAS Ctlgrs11045585
GMAF0.1662
Max Magnitude2
? (A;A) (A;G) (G;G) 28

[PMID 18294295] rs12762549 and rs11045585 can be used to predict whether docetaxel will induce leukopenia/neutropenia, according to a study of ~100 Japanese patients. When patients were classified into three groups by the scoring system based on the genotypes of these two SNPs, patients with a score of 1 or 2 were shown to have a significantly higher risk of docetaxel-induced leukopenia/neutropenia as compared to those with a score of 0 (P = 0.0000057; odds ratio [OR], 7.00; 95% CI [confidence interval], 2.95-16.59). This prediction system correctly classified 69.2% of severe leukopenia/neutropenia and 75.7% of non-leukopenia/neutropenia into the respective categories.

[Effect percentages provided in table are raw population fractions taken from the referenced study based on rs11045585 only. Total population size = 113. Breakdown: leukopenia/neutropenia: AA=20 AG=19; non-leukopenia/neutropenia: AA=63 AG=11]



[PMID 21691256] Pharmacokinetic and pharmacogenomic profiles of telmisartan after the oral microdose and therapeutic dose


[PMID 21468756] The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients.


[PMID 21673613] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.


[PMID 21829131] The impact of pharmacogenetics of metabolic enzymes and transporters on the pharmacokinetics of telmisartan in healthy volunteers.


GET Evidence
rs11045585
aa_change
aa_change_short
impact pharmacogenetic
qualified_impact Insufficiently evaluated pharmacogenetic
overall_frequency 0.148438
summary



[PMID 25648089OA-icon.png] Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy


[PMID 26475344OA-icon.png] CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer